NanoViricides is expected to report zero revenue and a consensus EPS of -$0.10, with its stock currently trading around $1.24, well below the $6.00 average analyst price target. Investors are primarily focused on the clinical enrollment and progress of NV-387, the company's lead broad-spectrum antiviral candidate in Phase II trials for Mpox and Ebola.

Management recently transitioned to an 'Orphan First' strategy, supported by FDA Orphan Drug designations for measles that could yield a valuable Priority Review Voucher. However, a limited cash position of roughly $2.98 million remains a key concern, as analysts watch for further dilution or financing needs to sustain operations through 2027.